Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Developing a national e-learning course in otorhinolaryngology: the Danish experience

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Ultra-high-fidelity virtual reality mastoidectomy simulation training: a randomized, controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. FDG-PET/CT in the surveillance of head and neck cancer following radiotherapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Value of pre- and intraoperative diagnostic methods in suspected glottic neoplasia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Chronic rhinosinusitis in COPD: A prevalent but unrecognized comorbidity impacting health related quality of life

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cochlear implant should not be absolute contraindication for electroconvulsive therapy and transcranial magnetic stimulation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Delayed Iatrogenic Intracranial Hypotension After Thoracotomy

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Developing a national e-learning course in otorhinolaryngology: the Danish experience

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The hallmark of neurofibromatosis type 2 (NF2) is bilateral vestibular schwannomas (VS) and severe hearing loss is common in NF2 patients. Vascular endothelial growth factor (VEGF) expression level in NF2 correlates with tumour growth rate and bevacizumab, a VEGF-binding antibody, has previously been shown to induce tumour shrinkage and improve hearing. We retrospectively reviewed the effect of bevacizumab on hearing and VS tumour size in 12 consecutive NF2 patients. Bevacizumab 10 mg/kg was administered intravenously every second week for 6 months; hereafter, bevacizumab 15 mg/kg was administered every third week. Patients were evaluated with repeated audiometries, MR scans and clinical evaluations. Radiological response was defined as a 20 % or greater reduction in VS volume. A total of 398 treatments (median 36) were administered and the median duration on therapy was 22 months (range 7-34). We observed a radiological response (≥20 % tumour shrinkage) in seven out of 18 tumours (39 %) in six out of 12 patients (50 %). Sustained radiological responses were maintained in six tumours (33 %) for more than 2 months. Three patients had objectively improved hearing and five patients reported subjective benefit in neurological symptoms, including improved hearing. Toxicity was in general manageable; however, one patient died from cerebral haemorrhage which was possibly related to therapy. In conclusion, bevacizumab improved hearing and reduced the size of VS in some patients with progressive NF2 which corroborates previous findings; however, the risk of severe side effects should be carefully considered and discussed with the patients prior to treatment.

Original languageEnglish
JournalEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
Volume272
Issue number12
Pages (from-to)3627-33
ISSN0937-4477
DOIs
Publication statusPublished - 2015

ID: 44956003